Omeros Receivables 2010-2024 | OMER
Omeros Annual Receivables (Millions of US $) |
|
---|---|
2024 | $8 |
2023 | $8 |
2022 | $213 |
2021 | $38 |
2020 | $4 |
2019 | $35 |
2018 | $23 |
2017 | $17 |
2016 | $12 |
2015 | $7 |
2014 | $0 |
2013 | $0 |
2012 | $2 |
2011 | $1 |
2010 | $1 |
2009 | $0 |
Omeros Quarterly Receivables (Millions of US $) |
|
---|---|
2024-12-31 | $8 |
2024-09-30 | $6 |
2024-06-30 | $8 |
2024-03-31 | $8 |
2023-12-31 | $8 |
2023-09-30 | $7 |
2023-06-30 | $11 |
2023-03-31 | $10 |
2022-12-31 | $213 |
2022-09-30 | $14 |
2022-06-30 | $14 |
2022-03-31 | $16 |
2021-12-31 | $38 |
2021-09-30 | $34 |
2021-06-30 | $32 |
2021-03-31 | $25 |
2020-12-31 | $4 |
2020-09-30 | $37 |
2020-06-30 | $16 |
2020-03-31 | $24 |
2019-12-31 | $35 |
2019-09-30 | $30 |
2019-06-30 | $29 |
2019-03-31 | $25 |
2018-12-31 | $23 |
2018-09-30 | $2 |
2018-06-30 | $2 |
2018-03-31 | $0 |
2017-12-31 | $17 |
2017-09-30 | $25 |
2017-06-30 | $19 |
2017-03-31 | $13 |
2016-12-31 | $12 |
2016-09-30 | $10 |
2016-06-30 | $9 |
2016-03-31 | $7 |
2015-12-31 | $7 |
2015-09-30 | $3 |
2015-06-30 | $3 |
2015-03-31 | $1 |
2014-12-31 | $0 |
2014-09-30 | $0 |
2014-06-30 | $0 |
2014-03-31 | $0 |
2013-12-31 | $0 |
2013-09-30 | $1 |
2013-06-30 | $1 |
2013-03-31 | $2 |
2012-12-31 | $2 |
2012-09-30 | $0 |
2012-06-30 | $1 |
2012-03-31 | $2 |
2011-12-31 | $1 |
2011-09-30 | $1 |
2011-06-30 | $2 |
2011-03-31 | $1 |
2010-12-31 | $1 |
2010-09-30 | $1 |
2010-06-30 | $1 |
2010-03-31 | $1 |
2009-12-31 | $0 |
2009-09-30 | $0 |
2009-06-30 | |
2009-03-31 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Products Manufacturing | $0.360B | $0.000B |
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Abbott Laboratories (ABT) | United States | $231.816B | 27.87 |
Boston Scientific (BSX) | United States | $152.176B | 38.10 |
Stryker (SYK) | United States | $145.393B | 30.40 |
EssilorLuxottica (ESLOY) | France | $127.544B | 0.00 |
Medtronic (MDT) | Ireland | $107.067B | 15.63 |
Lonza Group Ag (LZAGY) | Switzerland | $50.941B | 0.00 |
Haleon (HLN) | United Kingdom | $48.439B | 27.54 |
ResMed (RMD) | United States | $35.929B | 26.99 |
GE HealthCare Technologies (GEHC) | United States | $31.992B | 15.19 |
Agilent Technologies (A) | United States | $30.486B | 20.14 |
Terumo (TRUMY) | Japan | $28.205B | 0.00 |
Koninklijke Philips (PHG) | Netherlands | $23.066B | 16.58 |
Insulet (PODD) | United States | $21.859B | 85.82 |
Zimmer Biomet Holdings (ZBH) | United States | $18.837B | 12.10 |
Baxter (BAX) | United States | $15.857B | 11.84 |
Smith & Nephew SNATS (SNN) | United Kingdom | $12.412B | 0.00 |
Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
Demant (WILYY) | Denmark | $8.030B | 0.00 |
Bio-Rad Laboratories (BIO) | United States | $6.686B | 22.60 |
Lantheus Holdings (LNTH) | United States | $5.598B | 14.27 |
Prestige Consumer Healthcare (PBH) | United States | $4.325B | 19.27 |
Perrigo (PRGO) | Ireland | $3.713B | 9.41 |
Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
Haemonetics (HAE) | United States | $3.426B | 14.92 |
ICU Medical (ICUI) | United States | $3.404B | 25.10 |
Envista Holdings (NVST) | United States | $2.981B | 24.77 |
QuidelOrtho (QDEL) | United States | $2.451B | 16.90 |
GN Store Nord (GNNDY) | Denmark | $2.075B | 17.19 |
LeMaitre Vascular (LMAT) | United States | $1.813B | 40.54 |
AtriCure (ATRC) | United States | $1.534B | 0.00 |
Neogen (NEOG) | United States | $1.296B | 16.58 |
Green Thumb Industries (GTBIF) | United States | $1.173B | 26.38 |
Kestra Medical Technologies (KMTS) | United States | $1.164B | 0.00 |
AdaptHealth (AHCO) | United States | $1.156B | 11.75 |
BioLife Solutions (BLFS) | United States | $1.106B | 0.00 |
InMode (INMD) | Israel | $1.005B | 9.20 |
Phibro Animal Health (PAHC) | United States | $0.910B | 11.64 |
Evolus (EOLS) | United States | $0.632B | 0.00 |
CeriBell (CBLL) | United States | $0.575B | 0.00 |
Curaleaf Holdings (CURLF) | Canada | $0.557B | 0.00 |
Owens & Minor (OMI) | United States | $0.542B | 4.49 |
Valneva SE (VALN) | France | $0.541B | 0.00 |
Maravai LifeSciences Holdings (MRVI) | United States | $0.504B | 0.00 |
Tilray Brands (TLRY) | Canada | $0.431B | 0.00 |
Surmodics (SRDX) | United States | $0.383B | 0.00 |
Cresco Labs (CRLBF) | United States | $0.358B | 0.00 |
SNDL (SNDL) | Canada | $0.339B | 0.00 |
SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
Capricor Therapeutics (CAPR) | United States | $0.290B | 0.00 |
Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
VAREX IMAGING (VREX) | United States | $0.283B | 10.42 |
Aurora Cannabis (ACB) | Canada | $0.273B | 48.50 |
Sanuwave Health (SNWV) | United States | $0.257B | 0.00 |
Viemed Healthcare (VMD) | United States | $0.250B | 21.07 |
Verano Holdings (VRNOF) | United States | $0.248B | 0.00 |
Cerus (CERS) | United States | $0.247B | 0.00 |
ZimVie (ZIMV) | United States | $0.244B | 11.09 |
Canopy Growth (CGC) | Canada | $0.241B | 0.00 |
Biote (BTMD) | United States | $0.219B | 6.15 |
Quanterix (QTRX) | United States | $0.205B | 0.00 |
High Tide (HITI) | Canada | $0.194B | 0.00 |
OraSure Technologies (OSUR) | United States | $0.188B | 0.00 |
Utah Medical Products (UTMD) | United States | $0.176B | 14.18 |
Brainsway (BWAY) | Israel | $0.164B | 51.24 |
TriSalus Life Sciences (TLSI) | United States | $0.162B | 0.00 |
Organigram Global (OGI) | Canada | $0.158B | 0.00 |
FitLife Brands (FTLF) | United States | $0.147B | 18.16 |
Jin Medical (ZJYL) | China | $0.130B | 0.00 |
TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
Exagen (XGN) | United States | $0.103B | 0.00 |
Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
MacroGenics (MGNX) | United States | $0.090B | 0.00 |
Agape ATP (ATPC) | $0.078B | 0.00 | |
Fonar (FONR) | United States | $0.077B | 10.77 |
Veru (VERU) | United States | $0.074B | 0.00 |
Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
InterCure (INCR) | Israel | $0.072B | 0.00 |
Zynex (ZYXI) | United States | $0.063B | 0.00 |
United Health Products (UEEC) | United States | $0.059B | 0.00 |
Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
ImmuCell (ICCC) | United States | $0.046B | 0.00 |
Apyx Medical (APYX) | United States | $0.044B | 0.00 |
Modular Medical (MODD) | United States | $0.041B | 0.00 |
Rockwell Medical (RMTI) | United States | $0.038B | 56.00 |
United-Guardian (UG) | United States | $0.037B | 12.79 |
Safety Shot (SHOT) | United States | $0.037B | 0.00 |
Nephros (NEPH) | United States | $0.020B | 0.00 |
Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
INLIF (INLF) | $0.017B | 0.00 | |
Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
Flora Growth (FLGC) | United States | $0.013B | 0.00 |
Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
Senestech (SNES) | United States | $0.005B | 0.00 |
Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
Sharps Technology (STSS) | United States | $0.000B | 0.00 |
InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |